| Literature DB >> 30228579 |
Asim Ahmad1, Clint Daniel Kingsley2.
Abstract
In recent years, the choice of therapies for symptomatic Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) have grown exponentially, with no single agreed upon standard first-line therapy. The choice of therapy is often dictated by goals of care, patient characteristics and tumor genetic abnormalities. The goal of this article is to familiarize the primary care provider with some of the most commonly used therapeutic modalities with attention to the side effect profile of these regimens.Entities:
Mesh:
Substances:
Year: 2017 PMID: 30228579 PMCID: PMC6140236
Source DB: PubMed Journal: Mo Med ISSN: 0026-6620